Line Guénette1, Marie-Claude Breton2, Laurence Guillaumie3, Sophie Lauzier2, Jean-Pierre Grégoire2, Jocelyne Moisan2. 1. Faculty of Pharmacy, Laval University, Quebec City, QC, Canada; Chair on Adherence to Treatments, Population Health and Optimal Health Practices Research Unit, CHU de Québec Research Center, Quebec City, QC, Canada. Electronic address: line.guenette@pha.ulaval.ca. 2. Faculty of Pharmacy, Laval University, Quebec City, QC, Canada; Chair on Adherence to Treatments, Population Health and Optimal Health Practices Research Unit, CHU de Québec Research Center, Quebec City, QC, Canada. 3. Chair on Adherence to Treatments, Population Health and Optimal Health Practices Research Unit, CHU de Québec Research Center, Quebec City, QC, Canada; Faculty of Nursing, Laval University, Quebec City, QC, Canada.
Abstract
AIMS: To discern psychosocial factors of non-insulin antidiabetes drug (NIAD) adherence. METHODS: A cross-sectional study based on the theory of planned behavior (TPB). Adults with type 2 diabetes (T2D) who were members of Diabète Québec, a provincial association of persons with diabetes, and were prescribed at least one NIAD were invited to complete a web-based questionnaire. We measured variables ascertaining TPB constructs and other factors potentially associated with NIAD adherence (e.g., habit, social support, and mental health). NIAD adherence was assessed using the 8-item Morisky Medication Adherence Scale. Factors were identified using a multivariate logistic regression model. RESULTS: In our study, 901 participants (373 women; 515 retired; mean age: 62.7 years) with T2D for a mean of 10 years, completed the questionnaire. Participants exhibited a high intention to adhere to their NIAD treatment (mean score=5.8/6), positive attitudes toward adherence (mean score=5.5/6), and elevated perceived behavioral control in taking their medication (mean score=5.7/6). Only 405 (45%) participants reported high adherence (score=8/8). Perceived behavioral control, habit, older age, no perceived side effects, a longer period since T2D diagnosis and a lower number of NIAD daily doses were significantly associated with adherence (p<0.05). CONCLUSION: We identified several factors that may be modified for NIAD adherence and thereby provided insight into future adherence-enhancing intervention targets.
AIMS: To discern psychosocial factors of non-insulin antidiabetes drug (NIAD) adherence. METHODS: A cross-sectional study based on the theory of planned behavior (TPB). Adults with type 2 diabetes (T2D) who were members of Diabète Québec, a provincial association of persons with diabetes, and were prescribed at least one NIAD were invited to complete a web-based questionnaire. We measured variables ascertaining TPB constructs and other factors potentially associated with NIAD adherence (e.g., habit, social support, and mental health). NIAD adherence was assessed using the 8-item Morisky Medication Adherence Scale. Factors were identified using a multivariate logistic regression model. RESULTS: In our study, 901 participants (373 women; 515 retired; mean age: 62.7 years) with T2D for a mean of 10 years, completed the questionnaire. Participants exhibited a high intention to adhere to their NIAD treatment (mean score=5.8/6), positive attitudes toward adherence (mean score=5.5/6), and elevated perceived behavioral control in taking their medication (mean score=5.7/6). Only 405 (45%) participants reported high adherence (score=8/8). Perceived behavioral control, habit, older age, no perceived side effects, a longer period since T2D diagnosis and a lower number of NIAD daily doses were significantly associated with adherence (p<0.05). CONCLUSION: We identified several factors that may be modified for NIAD adherence and thereby provided insight into future adherence-enhancing intervention targets.